A Registry-study of ELZONRIS in Participants With BPDCN

Summary

The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.

Eligibility

Key Inclusion Criteria:

* Diagnosed with BPDCN, confirmed by hematopathology and biomarkers (inclusive of CD123, CD4, and CD56).
* Planning to start treatment with tagraxofusp monotherapy for BPDCN at the time of, or within 6 months prior to, informed consent form (ICF) signature or has started treatment.

Key Exclusion Criteria:

* Currently (or planning to) participating in another study or registry where BPDCN treatment outcomes are reported.
* Participating in an interventional clinical trial at the time of ICF signature.
* Known allergic reactions to components of tagraxofusp.

Note: Other protocol-specified criteria apply.

Conditions2

Interventions1

Related trials

• Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients — French Innovative Leukemia Organisation
• Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies — Therapeutic Advances in Childhood Leukemia Consortium
• Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML — Stanford University
• Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents — Joshua Zeidner
• A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax — Jacqueline Garcia, MD

Browse More Trials